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Abstract
OBJECTIVES—Completion rates for the human papillomavirus vaccine (HPV) series among 
adolescents remain low. Effectiveness of recall with parents choosing the method (preference-
based recall) for increasing HPV series completion is unstudied. Within a cluster-randomized trial, 
we examined effectiveness of preference-based recall compared with usual care for increasing 
series completion and the association of recall choices with completion.
METHODS—All Kaiser Permanente Colorado pediatric practices (n = 7) were randomized to 
intervention (n = 4) or control (n = 3) by using covariate-constrained randomization. From January 
to June 2013, parents at intervention practices whose adolescents received HPV 1 were asked the 
recall method they preferred for subsequent doses and if they also wanted their child reminded. 
Completion rates were assessed 1 year after HPV 1.
RESULTS—At intervention practices, 374 (43%) of 867 patients were enrolled; 39% preferred 
text, 18% e-mail, 9% auto-dialer, and 34% 2-methods; 19% chose to have adolescent also recalled. 
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Intervention adolescents were more likely to complete (63% vs 38%) than were controls (adjusted 
risk ratio 1.47 [1.38–1.57]) and less likely to be late in completing the series (45% vs 57%, P = .
02). Rates of completion were similar between different recall methods, but significantly higher 
for those preferring e-mail and phone compared withother methods (90% vs 60%. P = .008). 
Completion rates were similar for adolescents who also received recalls (62%) versus those who 
did not (63%).
CONCLUSIONS—Preference-based recall was effective in increasing HPV series completion 
rates, with point estimates substantially higher than for most published studies of reminder/recall.
Human papillomavirus (HPV) vaccines present an enormous opportunity to decrease the 
burden of cervical cancer precursors, cervical cancer, other anogenital cancer precursors and 
cancers, genital warts, and HPV-attributable oropharyngeal cancers.1 In the United States, 
263000 new cancers are attributable to HPV and >4000 women die of cervical cancer 
annually.2,3 Modeling studies predict marked reduction in HPV-associated cancers if high 
HPV vaccination rates can be achieved.4–7 Therefore, vaccination against HPV has been 
routinely recommended by the Advisory Committee on Immunization Practices for 
adolescent girls since 2007 and for adolescent boys since 2011.6,8 Each of the 3 HPV 
vaccines licensed are recommended as a 3-dose series, with the second dose administered 1 
to 2 months after the first dose and the third dose 6 months after the first dose.1
Despite the promise of HPV vaccines, rates of completion of the series remain 
disappointingly low. Among girls 13 to 17 years in 2013, 57.3% initiated the series and 
37.6% completed it.9 Among boys of the same age, 34.6% initiated and 13.9% completed.9 
Numerous barriers to vaccination have been identified.10–16 One of the major obstacles to 
series completion among adolescents is the need to have 3 visits within 6 months within a 
population that historically has low rates of health care visits.16–20 Patient reminder/recall 
(R/R), messages to parents and patients about needed upcoming (reminders) or overdue 
vaccinations (recalls), may be a particularly important tool for assisting in completion of the 
HPV series.
The effectiveness of R/R for increasing vaccination rates has been demonstrated in 
numerous studies for childhood, adolescent, and adult vaccines,21–31 but there has been 
limited examination of the effectiveness of R/R for increasing HPV series completion. In 
addition, preference-based R/R, in which parents choose the method of reminder or recall 
they prefer, has not, to our knowledge, been evaluated in a randomized controlled trial. The 
objectives of the current study were (1) to describe parental preferences for HPV recall; (2) 
to assess the effectiveness of preference-based recalls compared with usual care for 
increasing HPV series completion (primary outcome) and timeliness of vaccination; and (3) 
within the intervention group, to assess the association of different recall choices with series 
completion.
METHODS
The study was approved by the Kaiser Permanente Colorado (KPCO) and the Colorado 
Multi-Institutional Review Boards as requiring verbal parental consent only.
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Study Setting and Population
This was a cluster randomized pragmatic trial, with randomization at the level of the 
practice, involving all pediatric practices (n = 7) within a large integrated health care system, 
KPCO. Enrollment was active in the intervention group, whereas all members of the control 
group were passively enrolled. Practices were randomized to intervention (n = 4) or control 
(n = 3) by using covariate constrained randomization to balance study arms on available 
baseline characteristics.32–36 Covariates included in the randomization were the number of 
active patients ages 11 to 17, the proportion of patients self-reporting as African American 
and Hispanic, the proportion of adolescents at baseline with ≥1 doses of HPV, and the 
proportion of patients with Medicaid insurance. Eligible patients in both the intervention and 
control arms included adolescents between ages 11 and 17 who were enrolled at KPCO 
within the past 2 years and who received their first HPV dose between January and June 
2013.
Descriptions of Intervention and Usual Care
To minimize confusion for families who were already planning to return, the intervention 
was focused on recalling adolescents who were late for HPV doses. Because KPCO was 
interested in the sustainability of the intervention, only the usual clinic staff, including 
medical assistants or nurses, were involved with enrollment. Although it was encouraged 
that all parents be asked about participation, if patient volumes were extremely high, the 
clinic was understaffed, or there were substitute staff, parents may not have been approached 
about enrollment. In addition, KPCO determined it was not feasible for clinic personnel to 
collect reasons for nonenrollment.
Parents of eligible adolescents receiving their first HPV vaccine at intervention practices 
were told by the medical assistant or nurse giving the vaccine that KPCO was doing a study 
to see how best to remind parents and adolescents about getting future HPV doses and asked 
if they wished to be recalled for future doses. Adolescents who were not accompanied by a 
parent were not asked to participate. Parents who wanted to receive reminders were given a 
short check-off form clarifying (1) which recall method they preferred (text, e-mail, 
automated telephone message), (2) if they also wanted a recall sent to their child, and (3) the 
contact information for their preferred method. Parents were told they could select up to 2 
methods and that, if they wanted to have their adolescent reminded, they had to pick the 
same method for both. The number of recalls parents would receive was not specified.
For recalls, KPCO used an Interactive Voice Response (IVR) system, which is capable of 
producing multiple automated recall messages. If a single recall method was chosen, a recall 
was sent on alternating weeks, for up to 3 recalls per 6 weeks. If 2 methods were chosen, 6 
recalls were sent, 1 each week, alternating between the 2 preferred recall methods, for up to 
6 weeks. Recalls for dose 2 began 9 weeks after dose 1 and for dose 3, 18 weeks after dose 
2. Health clinics randomized to the usual care arm did not implement reminders or recalls 
for HPV vaccine.
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Outcomes
The primary study outcome was a comparison of series completion rates among adolescents 
age 11 to 17 in the intervention and usual care arms 1 year after the first HPV dose was 
received. Analyses were intention-to-treat for all enrolled patients, regardless of whether the 
intervention was received. Completion rates for HPV 2 dose were also assessed. 
Immunization rates were assessed by using KPCO administrative electronic medical record 
data and data from the Colorado Immunization Information System for both study arms. 
Patients were considered late for each dose if they exceeded the minimum recommended 
interval by 2 months.37 For the intervention group only, we also assessed differences in HPV 
completion rates by IVR recall method, contact person (parent only versus parent/child), age 
group, gender, and race/ethnicity.
Analysis
Generalized linear mixed models (SAS GLIMMIX procedure) were used to assess 
differences in HPV dose 2 and dose 3 completion rates. Models were adjusted for gender, 
age as a continuous variable, and race/ethnicity and the random effect of clinic site. Relative 
risks were generated by using a log link with a binomial distribution in the regression model.
38
 Secondary analyses were performed to examine differences in HPV completion rates and 
recall and contact preferences among intervention participants. A χ2 test of proportions was 
used for comparisons between categorical/dichotomous variables. All analyses were 
conducted by using SAS (SAS 9.3; SAS Institute, Inc, Cary, NC).
RESULTS
As shown in Fig 1 (consort diagram), parents of 43% (374/867) of eligible adolescents were 
enrolled at the 4 intervention sites and data from 555 eligible adolescents were assessed at 
the 3 control sites. Table 1 compares characteristics of the intervention group enrolled with 
adolescents at intervention sites who were not enrolled and with adolescents at the control 
sites. Adolescents from intervention sites who were not enrolled were slightly older, largely 
because older adolescents were more likely to come without a parent and, therefore, would 
not be eligible for enrollment. Nonenrolled adolescents from intervention sites were also 
more likely to have unknown race/ethnicity, because this information was not checked at 
enrollment. The intervention enrolled and control groups were well matched with respect to 
gender and age, but there were statistically significant, although relatively minor, differences 
in race and ethnicity between the groups. Baseline rates at the time of study initiation for 
HPV dose 1 were 18% in the intervention sites (total n = 7577) and 20% in the control sites 
(total n = 103875, P < .01); series completion rates at baseline were 6% and 7%, respectively 
(P < .01).
Parental Preferences for Recall Method
Text alone was requested by 39% of parents, followed by text and e-mail (19%), e-mail only 
(18%), text and phone (9%), phone only (9%), or phone and e-mail (6%). As shown in Table 
2, parents who chose text messaging were more likely to report their adolescents to be of 
Hispanic ethnicity (27%) versus all other methods (12%). Parents of white adolescents were 
more likely to prefer methods other than text messaging. Nineteen percent of parents 
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preferred their adolescent to be reminded in addition to them. Parents of older versus 
younger adolescents were more likely to ask for their adolescent to be reminded in addition 
to themselves. Parents who requested that their child be reminded were more likely to 
choose a method involving text (80%), compared with parents who chose not to remind their 
child (64%, P = .01).
Effectiveness of Preference-Based Recall Compared With Usual Care on HPV Series 
Completion
Table 3 compares the percentage receiving doses 2 and 3 for intervention versus control 
groups, as well as adjusted relative risks for these comparisons. Rates of completion for 
adolescents at intervention sites that were not enrolled (33%) were similar to the control 
group (38%) and the adjusted relative risk for HPV completion for the intervention enrolled 
group compared with the intervention not enrolled group was 1.82 (P < .001). Because of the 
possibility of selection bias in the intervention groups related to lack of uniform enrollment, 
we also assessed differences in HPV series completion rates for all adolescents at the 
intervention sites, both enrolled and unenrolled, compared with control sites. Completion 
rates were 46% versus 38% with an adjusted risk ratio of 1.22 (P < .01).
Timeliness of Vaccination
As shown in Table 4, adolescents in the intervention group were more likely to receive 
vaccines within the recommended dosing intervals for doses 1 to 2 (P < .001), doses 2 to 3 
(P = .02), and doses 1 to 3 (P = .01).
Association of Different Recall Choices With Series Completion
As shown in Table 5, the only recall method that was associated with higher series 
completion rates was the combination of phone and e-mail, which did differ significantly 
when compared with all other groups (P < .01). Rates of completion were higher for younger 
adolescents (P < .01) but did not differ significantly by other factors examined.
DISCUSSION
For the promise of the HPV vaccine to be realized, rates of vaccine initiation and series 
completion must be markedly increased. The current study demonstrates that a preference-
based recall intervention, including options for text, e-mail, or automatic telephone 
messages, instituted at the time of initiation of the HPV series, resulted in increases in series 
completion that were higher than those achieved by most published R/R studies for other 
vaccines. In addition, the intervention resulted in more timely completion of the series. The 
intervention was most effective for younger adolescents, and reminding the adolescent in 
addition to the parent did not increase effectiveness.
Numerous studies have demonstrated the effectiveness of R/R in increasing immunization 
rates for a variety of vaccines; however, there are limited data about its utility in achieving 
HPV series completion. Studies conducted in the first few years after HPV was first 
recommended by using text or a mixture of mail and telephone reminders, showed either no 
or small effects.23,39,40 A more recent study, conducted in 2013–2014, within a large 
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managed care population demonstrated a 10% increase in completion rate for HPV vaccine 
among those needing either 1 or 2 doses of the series.41 Similar to our findings, this study 
also observed a higher rate of effectiveness among younger adolescents.
Our study showed substantially higher effect sizes than most previous R/R trials for any 
vaccine, with an absolute increase of 25 percentage points for HPV completion among 
adolescents in the intervention group. There are a number of possible reasons for this large 
effect size. To our knowledge, this is the first randomized trial to study a preference-based 
recall model in which parents were allowed to choose the method of contact, although 1 
previous study examined the effectiveness of methods chosen by parents in a nonrandomized 
fashion.42 Allowing parents to choose the R/R method may increase the likelihood that they 
actually hear or see the message, as well as their receptivity to responding. In addition, the 
population being studied had initiated the series and were, therefore, potentially more 
receptive to recalls than populations who had never previously received a particular vaccine. 
This trial was also conducted within a health care delivery system with a high level of 
experience with the use of IVR systems and e-mails to patients, which may have contributed 
to parental receptivity. In addition, characteristics of the population enrolled in KPCO may 
have played a role, although the direction of potential influences of sociodemographic 
factors based on previous literature could be postulated to either increase or decrease the 
effect size. The study population was insured and lived in census tracts with a median family 
income of $743900 (SD $323420), as assessed by using geocoding to estimate area-based 
socioeconomic measures.43,44 Historically, studies comparing mail and telephone R/R 
interventions have shown higher effectiveness in high-income versus lower income 
populations.25,45–47 However, the present trial used mobile health technologies as the 
predominant R/R methods, which have been shown to be used at a higher rate in low-income 
and younger populations.48–51 In particular, text messaging has been shown to be especially 
effective in low-income minority populations who are more likely to be cell-phone–only 
users and to use text messaging compared with high-income nonminority populations.52–54 
Therefore, it is reasonable to think that our data may be generalizable to low-income and 
minority populations.
Our data regarding parental preferences for recall method must be examined in the context 
of previous survey data assessing theoretical choices about reminder or recall methods. In a 
cross-sectional national survey of parents of 0- to 17-year-olds conducted in 2010, roughly 
one-third preferred mail, one-third telephone, 16% e-mail, and only 3% text; 44% were 
unwilling to register their cell phone numbers and, among these, cost of minutes was a 
prominent concern.55 In a 2011 survey in 7 Colorado counties of parents of children 19 to 35 
months 58% preferred mail, 17% telephone, 13% e-mail, and 11% text, although 60% were 
“okay with” being contacted by e-mail and 46% by text on their cell phones.56 There were 
significant differences between urban and rural parents, with urban parents being more likely 
to prefer text or e-mail option. In a third survey conducted in 2011 in an urban setting with a 
primarily Latino and low-income patient population, most parents reported owning a cell 
phone with text messaging capabilities (89%), had unlimited messaging plans (85%), and 
reported being comfortable receiving text messages (88%) or e-mailing with a provider 
(84%) about health-related issues.57 Among parents in our study, there was a clear 
preference for text messages and, less commonly, e-mail messages, with phone being a 
Kempe et al. Page 6
Pediatrics. Author manuscript; available in PMC 2018 April 04.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
distant third. Taken together, these cumulative data underline the fact that context and patient 
characteristics are extremely important in determining the optimal methods for R/R. In 
addition, technology is changing quickly, with populations in some parts of the country 
routinely having no limitations in their texting plans, whereas for others this is still a 
limitation.
This study has important limitations. Because a moderate proportion of patients in the 
intervention clinics were not recruited to participate, it is possible that selection bias 
contributed to our findings. Similarly, being unable to recruit adolescents seen alone could 
also produce selection bias. However, when including all patients from intervention clinics 
(whether successfully recruited or not) in analyses, which would effectively eliminate the 
risk of selection bias, a significant intervention effect was still seen. In addition, we were 
able to show that outcomes in the unenrolled eligible groups resembled the control group 
and that comparisons between the enrolled and unenrolled resembled those between the 
enrolled and control groups, suggesting that selection bias was not a large factor. It is also 
possible that randomization at the level of the clinic did not distribute known and unknown 
confounders equally between intervention and control arms. However, baseline HPV 
vaccination rates were in fact slightly higher in control clinics, which would, if anything, 
bias results toward the null.
In addition, the patient populations and setting of our study may not be generalizable to 
other settings. We did not examine preference-based recall with respect to initiation of the 
HPV series, only its effect on series completion. Our intervention focused on recalling 
adolescents overdue for HPV doses rather than reminding them of upcoming doses; it is 
possible that reminders combined with recall notices would have increased the timeliness of 
series completion. Although we did not show a difference in success of recall based on 
whether the adolescent was recalled in addition to the parent, only one-fifth of parents 
agreed to the recalling of the adolescent directly. It is possible that the addition of the 
adolescent could make a difference if broadly applied across populations. Finally, this 
intervention relied on the use of an existing IVR system, which facilitated tailoring methods 
of R/R and personalizing messages. Although our study did not examine cost, a previous 
IVR-based reminder effort at KPCO using the same system estimated cost per reminder 
ranged from $0.05 to $1.23, depending on the volume of calls being generated.58 IVR 
services are also available from IVR vendors, without the need to purchase an entire IVR 
system, but practices may not be willing or able to pay for this type of service. In the 
absence of IVR technology, practices would need to use office personnel to implement 
preference-based R/R, which could limit widespread adoption.
Results of this study demonstrate that preference-based recall could have a major impact on 
increasing HPV series completion rates and in increasing the timeliness of full vaccination. 
Whether this method could also increase initiation of the series also should be examined, as 
barriers to initiation and to completion have been shown to differ.10,59–61 Preference-based 
R/R may have much broader applicability in primary care. If preferences were collected and 
electronically captured at the time of new patient enrollment, preference-based R/R could be 
broadly applied for both preventive and follow-up reminders or recalls for many patient 
populations. This aligns well with the Centers for Medicare and Medicaid Services financial 
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incentives for practices that meet Meaningful Use criteria, as 1 criterion is the 
implementation of reminders or recalls to patients for preventive care and follow-up care 
according to their method of preference.62 With almost universal access to mobile phones 
and increasing use of smart phones among most patient populations, increased stability of 
mobile phone numbers over landline numbers or addresses and availability of low-cost 
texting programs,55 such methods may become a mainstay for increasing delivery of 
preventive services.
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FIGURE 1. 
Consort diagram.
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TABLE 3
HPV 2 and 3 Completion
HPV Intervention, Enrolled, n = 374, % Control, n = 555, % Adjusteda Relative Risk (95% CI) P
Received dose 2 83 71 1.14 (1.07–1.22) <.001
Received dose 3 63 38 1.59 (1.39–1.83) <.001
CI, confidence interval.
aAdjusted for age, gender, race, and ethnicity.
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TABLE 4
Timeliness of HPV Vaccination
Dosing Interval Definition of Adherence, moa Percent Late for Vaccine Intervention Control, % Pb
Doses 1–2 1–3 47 65 <.001
Doses 2–3 3–5 48 58 .02
Doses 1–3 6–8 45 57 .01
aOne month equivalent to 30.5 days.
bAdjusted for age, gender, race and ethnicity.
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TABLE 5
Completion Rates by Method, Patient Characteristic, and Preference (Intervention Only)
Characteristic Level HPV Dose 2 Completed, n = 312 HPV Dose 3 Completed, n = 223
% (n) % (n)
Contact preference Parent and child 85.9 (61) 62.1 (41)
Parent only 82.8 (251) 62.5 (182)
Age, ya 11–12 86.4 (152) 70.8 (119)
13–15 81.7 (107) 58.9 (73)
16–17 79.1 (53) 47.7 (31)
Gender Boys 81.2 (203) 62.0 (147)
Girls 87.9 (109) 63.3 (76)
Race White 86.2 (156) 64.5 (111)
Black 86.3 (44) 57.4 (27)
Other 81.2 (56) 67.6 (46)
Unknown 76.7 (56) 55.7 (39)
Hispanic Yes 77.8 (63) 60.8 (48)
No 85.8 (223) 65.2 (161)
Unknown 78.8 (26) 45.2 (14)
Type of contact One method 82.5 (203) 59.1 (137)
Two methods 85.2 (109) 68.8 (86)
Contact methodb Text only 82.1 (119) 56.2 (77)
E-mail only 85.1 (57) 60.7 (37)
Phone only 79.4 (27) 67.6 (23)
Text and e-mail 81.9 (59) 64.3 (45)
Text and phone 85.7 (30) 65.7 (23)
Phone and e-mail 95.2 (20) 90.0 (18)
aP < .01, distribution of age statistically different between completed and not completed for HPV dose 3.
bP = .008 for phone and e-mail versus all other contact methods for dose 3 completion.
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